

## **Emergency Dosing Recommendations for Treatment and Prophylaxis of Influenza in Pediatric Patients less than 1 year old \***

Dosages shown in the following tables are based on age, not on weight<sup>1</sup>, and are for use with the TAMIFLU<sup>®</sup> Oral Suspension formulation (12 mg/mL).

### **Treatment**

Treatment is recommended for 5 days and should begin within 2 days of developing symptoms.

### **Recommended Treatment Doses for Pediatric Patients less than 1 year old**

<b>Body Weight (kg)</b>	<b>Dose by Age</b>	<b>Recommended Treatment Dose for 5 Days †</b>
Dosing for infants younger than 1 year not based on weight	6-11 months	25 mg twice daily
	3-5 months	20 mg twice daily
	< 3 months	12 mg twice daily

### **Prophylaxis**

Prophylactic treatment for pediatric patients who have been in close contact with an infected individual is recommended for 10 days. Prophylactic treatment should begin within 2 days of exposure.

### **Recommended Prophylactic Doses for Pediatric Patients less than 1 year old**

<b>Body Weight (kg)</b>	<b>Dose by Age</b>	<b>Recommended Prophylaxis Dose for 10 Days †</b>
Dosing for infants younger than 1 year not based on weight	6-11 months	25 mg once daily
	3-5 months	20 mg once daily
	< 3 months	Not recommended unless situation judged critical

†For infants less than 1 year old, a measuring device (such as a 5-mL oral syringe) must be used that will dispense 2 mL (about 25 mg), 1.6 mL (about 20 mg) or 1 mL (12 mg).

Please refer to the [\*\*TAMIFLU<sup>®</sup> FACT SHEET FOR HEALTH CARE PROVIDERS\*\*](#) for instructions on the preparation of TAMIFLU<sup>®</sup> for Oral Suspension

<sup>1</sup> The [technical review of the Emergency Use Authorization \(EUA\) for Tamiflu<sup>®</sup>](#) further explains the basis for the emergency dosing recommendations for pediatric patients less than 1 year old.

\*Excerpted from the Tamiflu<sup>®</sup> (oseltamivir phosphate) EUA (as amended), Fact Sheet for Healthcare Providers, Authorized by FDA on April 27, 2009. These instructions are authorized for use subject to the terms and conditions of the [EUA](#).